Publications by authors named "Yingxiang Shao"
Background: Siglec-E is an immune checkpoint inhibitory molecule. Expression of Siglec-E on the immune cells has been shown to promote tumor regression. This study aimed to develop an adenovirus (Ad) vaccine targeting Siglec-E and carbonic anhydrase IX (CAIX) (Ad-Siglec-E/CAIX) and to evaluate its potential antitumor effects in several preclinical renal cancer models.
View Article and Find Full Text PDFInterferon-induced protein 35 (IFI35), an immunomodulator, is highly expressed in tumor cells, yet its role in enhancing tumor vaccine efficacy remains unclear. In this study, an adenovirus (Ad) vaccine encoding dual targets, IFI35 and carbonic anhydrase IX (CAIX), was developed for renal carcinoma treatment. Co-immunization with Ad-IFI35/CAIX effectively inhibited tumor growth in a subcutaneous model and significantly increased the infiltration of CD8 T cells and dendritic cells (DCs).
View Article and Find Full Text PDFArticle Synopsis
- Vaccines focused on immune checkpoints, specifically targeting B7H1 and B7H3, are being tested for their effectiveness against renal carcinoma.
- In mouse and humanized models, the Ad-B7H1/B7H3 vaccine successfully inhibited tumor growth and bolstered CD8 T cell immune responses.
- The study indicates that this vaccine shows significant promise as a treatment for solid tumors, with strong evidence of its effectiveness in various cancer models.
Adenovirus vaccine targeting kinases induces potent antitumor immunity in solid tumors.
J Immunother Cancer
August 2024
Article Synopsis
- Targeting kinases with adenovirus vaccines encoding Aurora kinase A (AURKA) and cyclin-dependent kinase 7 (CDK7) shows potential in treating solid tumors in mouse and humanized models.
- Co-immunization with these vaccines not only prevented tumor growth but also enhanced T-cell immunity and immune cell infiltration in various tumor types.
- The study highlights the effectiveness of the Ad-AURKA/CDK7 vaccine as a promising therapeutic strategy, showcasing its ability to generate long-lasting antitumor responses through CD8 T cells.